I agree to the Privacy & Cookies Policy, Terms of Use, Disclaimer & Privacy Policy and to receive emails from Finder Under the terms of its public-private partnership with the US Department of Health and Human Services (HHS), Seqirus can deliver 150 million influenza vaccine doses to the US government to support an influenza pandemic response within 6 months. It was originally approved by the FDA in 2020 in a single dose, pre-filled syringe (PFS) presentation.Īirborne respiratory diseases such as influenza have been a focus of public health systems worldwide since the COVID-19 pandemic spread in March 2020 and the fresh approval is expected to bolster Seqirus’ product line. The biotech giant’s shares have likely lifted on Wednesday after its influenza vaccine business, Seqirus, overnight announced it had received approval from the the US Food and Drug Administration (FDA) for the Audenz vaccine.Īudenz is the first-ever adjuvanted, cell-based influenza vaccine to help protect individuals 6 months and older against influenza A(H5N1) in the event of a pandemic and is available in multi-dose vial (MDV) form. The stock was up more than 1% to $319.78 in early trading. Shares in CSL ( ASX: CSL) are among the list of most traded stocks on the ASX on Wednesday, building on the recent momentum that has seen the already expensive stock gain over 7% in the past month. Shares in biotech giant CSL are up 7% in the past month alone.
0 kommentar(er)
